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ABSTRACT The drug discovery process for drugs that target
the central nervous system suffers from a very high rate of failure
due to the presence of the blood–brain barrier, which limits the
entry of xenobiotics into the brain. To minimise drug failure at
different stages of the drug development process, new meth-
odologies have been developed to understand the absorption,
distribution, metabolism, excretion and toxicity (ADMET) profile
of drug candidates at early stages of drug development.
Additionally, understanding the permeation of drug candidates
is also important, particularly for drugs that target the central
nervous system. During the first stages of the drug discovery
process, in vitro methods that allow for the determination of
permeability using high-throughput screening methods are ad-
vantageous. For example, performing the parallel artificial mem-
brane permeability assay followed by cell-based models with
interesting hits is a useful technique for identifying potential
drugs. In silico models also provide interesting information
but must be confirmed by in vitro models. Finally, in vivo
models, such as in situ brain perfusion, should be studied to
reduce a large number of drug candidates to a few lead
compounds. This article reviews the different methodologies
used in the drug discovery and drug development processes
to determine the permeation of drug candidates through the
blood–brain barrier.
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ABBREVIATIONS
ADMET Absorption, distribution,
metabolism, excretion and toxicity
AJ Adherens junctions
AMT Adsorptive-mediated transcytosis
ATP Adenosine triphosphate
BBB Blood–brain barrier
BCRP Breast cancer resistance protein
CNS Central nervous system
CSF Cerebrospinal fluid
GLUT Glucose transporter
LAT Large aminoacid transporter
LDL Low density lipoprotein
MRP Multidrug resistance associated protein
NCE New chemical entities
OATP Organic anion transporter protein
PAMPA Parallel artificial membrane
permeability assay
PEG Polyethylene glycol
P-gp/ABCB1 P-glycoprotein
PK Pharmacokinetics
PVDF Polyvinylidene fluoride
RMT Receptor-mediated transcytosis
TEER Transendothelial resistance
TJ Tight junctions
UWL Unstirred water layer
INTRODUCTION
The high attrition rate of drug candidates during all stages of
the drug development process is a critical issue for both
economic and treatment reasons. It has been shown that
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the major factor leading to the attrition of new chemical
entities (NCEs) during drug development does not necessar-
ily result from a lack of drug activity but is rather a result of
inadequate pharmacokinetic (PK) properties (1). Particularly
for central nervous system (CNS) diseases, the lack of per-
meation through the BBB prevents the active compound
from reaching its target. Because of the huge costs asso-
ciated with bringing a drug to market, it is important to
fully characterise the ADMET (absorption, distribution,
metabolism, excretion, toxicity) profile of candidate drugs
as early as possible during the drug discovery process. A
thorough ADMET evaluation decreases the risk of attri-
tion during clinical phases or even possible withdrawal
from the market (2). ADMET issues are even more
important for drug candidates that target the central
nervous system (CNS). Only 3 to 5% of CNS drug
candidates that enter phase I clinical trials are success-
fully launched compared to approximately 10% for all
compounds (2,3). The particular organisation of endo-
thelial cells, which are connected by tight junctions and
form the blood–brain barrier (BBB), is a further obstacle
to the CNS penetration of drug candidates. Combined
with numerous transporters, such as efflux and uptake
transporters, and drug-metabolising enzymes present at
the luminal side of the BBB, penetration of the BBB is a
treatment issue for CNS diseases, such as Alzheimer’s
disease, Parkinson’s disease and Huntington’s disease.
By contrast, when other organs are targeted, it is critical that
BBB penetration is either null or reduced to limit adverse
effects. Therefore, determining the distribution of a drug in
and around the brain is important when developing a new
compound.
Different methodologies exist to evaluate the permeation
potential of new chemical entities. The choice of strategy
relies primarily on the type of throughput (driven by the
number of compounds that require testing) and the type of
information needed. This implies that scientists should mas-
ter these strategies to choose the proper methodology based
on the information required, and they should be able to
correctly interpret the results. Here, we review the different
methods available for physicochemists, biologists and
ADMET scientists at different stages of the drug discovery
and development processes to select drug candidates that
penetrate the BBB. After describing the physiology of the
blood–brain barrier, in silico, in vitro and in vivo approaches to
determine BBB permeation will be explored. Drawbacks and
advantages will be critically examined, and key experi-
mental and/or interpretation points will be highlighted.
Finally, because an increasing number of strategies to
enhance drug penetration require complex formulations,
such as micro/nano-carriers, application of these different
screening methods to modern drug development efforts will
be discussed.
PHYSIOLOGY OF THE BLOOD–BRAIN BARRIER
(BBB)
In 1885, the studies of Paul Ehrlich first highlighted the
presence of the BBB. In his studies, Ehrlich intravenously
injected various dyes, and he observed that almost the entire
body was stained but not the brain (4,5).
Edwin Goldman, a student of Ehrlich’s, continued this
research using the dye trypan blue. He found that after
intravenous injection of the dye, the choroid plexus and
meninges were stained; however, no dye was recovered in
either the brain or cerebrospinal fluid (CSF) (6). In another
experiment, he injected the dye directly into the CSF and
found that the entire brain was stained but not the rest of the
body (7). These experiments demonstrated the existence of a
biological barrier between the brain and the rest of the
systemic circulation, the blood–brain barrier.
Over many years of research, our knowledge of the BBB
has increased, and scientists are now aware that the BBB is a
structure with complex cellular organisation that separates
the brain parenchyma from the systemic circulation. It is of
key importance for the maintenance of brain homeostasis,
which is essential for good neuronal and synaptic activities
(8–12), and represents the main route by which compounds
reach the CNS. Moreover, the BBB also acts as a metabolic
barrier due to the presence of numerous enzymes (13,14),
including peptidases, γ-glutamyl transpeptidase (γ-GT), al-
kaline phosphatase (ALP), nucleotidases, cytochromes P450
(CYP450) and monoamine oxidase (MAO). These enzymes
can either metabolise potentially harmful drugs to inactive
CNS compounds, convert an inactive drug to its active CNS
metabolite or degrade them into metabolites or substrates of
specific efflux transporters, such as the P-glycoprotein or
multidrug resistance proteins.
The BBB consists of brain capillaries that support endo-
thelial cells and are surrounded by astrocytic end-foot pro-
cesses (15). It is the central part of the neurovascular unit,
which is responsible for communication between endothelial
cells, astrocytes, pericytes and neurons (14).
Endothelial Cells and Tight Junctions
The specificity of the endothelial cells comprising the blood–
brain barrier compared to the endothelial cells in the rest of
the body is based on their organisation. Cerebral endothelial
cells are connected by intercellular proteins. Occludins,
claudins and junctional adhesion molecules, together with
cytoplasmic accessory proteins, including zonula occludens-
1 (ZO-1), ZO-2, ZO-3 and others, are transmembrane pro-
teins that are responsible for the formation of tight junctions
(TJs) (14) that seal the paracellular pathway (16–18) and
make the brain nearly inaccessible to polar compounds that
are not the substrates of specific transporters (19). Adherens
2730 Bourdonnec, Carrupt, Scherrmann and Martel
junctions (AJs) also contribute to the junction complex by
joining themembrane proteins, cadherins, to the intermediary
proteins, catenins, to form adhesive linkages between endo-
thelial cells (20). The TJs in cerebral capillaries are approxi-
mately 50 to 100 times tighter than the TJs in peripheral
capillaries (21) and lead to a high transendothelial electrical
resistance (TEER) of approximately 1,500–2,000Ω.cm2 com-
pared to 3–33Ω.cm2 for other tissues (22,23), which is due to
the restriction of small ions, such as Na+ and Cl−, from passing
through the TJs. Moreover, BBB endothelial cells differ from
other endothelial cells in the low number of endocytotic in-
vaginations at the luminal portion of the cell membrane,
which leads to very limited pinocytic transcellular transport
(12,20,24–28), a large number of mitochondria (29) and the
polarised expression of transporters and receptors for active
transport (30). Indeed, the brain endothelium has only 3–6
pinocytic vesicles per μm3 compared to 82–93 per μm3 for the
peripheral endothelium (31,32).
Many transmembrane proteins are expressed on the lu-
minal and abluminal membranes of the endothelium to
transport nutrients that are essential for the brain and to
eliminate waste products of metabolism. In particular, pro-
teins, such as GLUT-1 (glucose transporters), transport polar
nutrients; Na-ATPase and K-ATPase transport sodium and
potassium ions respectively; insulin or transferrin receptors
transport proteins (8,24,28,33,34), and organic anion
transporting proteins (OATP) (35) transport hormones, opi-
oids, steroids, statins, cardiac glycosides, anticancer drugs
and antibiotics (15). These transporters all play important
roles in the maintenance of cerebral equilibrium. Moreover,
efflux transporters, such as P-gp/ABCB1(36) or BCRP (37)
are highly expressed on the luminal side of endothelial cells.
Astrocytes, Pericytes and Basal Lamina
Astrocytes are important cellular constituents of the
neurovascular unit. They are linked to interneurons and thus
the entire cerebral microenvironment (19). Astrocytes repre-
sent approximately 50% of the total mammalian brain vol-
ume (38). Moreover, some studies indicate that astrocytes
play a role in the upregulation of BBB properties, such as
tighter tight junctions (39,40) and the expression of specific
polarised transporters, such as P-gp/ABCB1(14) and the
enzymatic system (14,19), due to astrocyte-endothelial cell
interactions. This upregulation of BBB properties by astro-
cytes is synergistic with pericytes, neurons and perivascular
macrophages (41). Astrocytes also have different functions,
such as the formation of and activity at synapses, energetic
and redox metabolism, intercellular communication, ho-
meostasis (38) and glucose transport from the systemic circu-
lation to the brain.
Similar to astrocytes and neurons, pericytes are part of the
neurovascular unit and play a role in the maintenance of
both BBB properties and cerebral homeostasis. Recent stud-
ies have also indicated a role for pericytes in haemostasis, as
well as in immune and phagocytic processes (20,42).
Pericytes surround endothelial cells and both cell types are
supported by the basal lamina. The integrity of basal lamina
allows the maintenance of BBB properties, due to its anchor-
ing role, but the basal lamina does not have a significant
impact on the permeability of the BBB. However, under
specific pathological conditions or in response to an aggres-
sive stimulus, its thickness can vary, which perturbs the
normal function of the BBB (42).
MECHANISMS OF TRANSPORT
THROUGH THE BBB
The BBB is one of the most important barriers in the body.
The permeation of drugs through the BBB is subject to
strong selection depending on the physicochemical proper-
ties of the compound, such as lipophilicity, molecular weight,
permeability coefficient (logPe), molecular volume,
ionisation state, and/or their aff inity to specif ic
transporters(efflux or uptake transporters) that are present
in the cellular space (43–45). Therefore, the BBB may not be
as impermeable as indicated by the first experiments with
dyes. The cellular organisation of the BBB and the presence
of transmembrane proteins enable a selective regulation of
the passage of molecules from the blood to the brain. This is
of particular importance for the uptake of essential nutrients
or active CNS drugs and protects the brain from undesirable
compounds, which could be toxic to the CNS.
The specificities of brain capillaries makes of the BBB an
effective and efficient barrier that limits the entry of xenobi-
otics into the brain. Molecules present in the blood stream
can reach the CNS by two different pathways, the
paracellular pathway, which is between 2 endothelial cells
through the tight junctions, or the transcellular pathway,
which is through an endothelial cell.
Molecules that reach the CNS via the transcellular path-
way can diffuse passively, can be actively transported by
specific transporters or can undergo endocytosis. For exam-
ple, small lipophilic molecules, such as O2 and CO2, or very
small compounds, such as ethanol, water or diverse lipophilic
drugs, can freely diffuse through the lipid barriers of endo-
thelial cells (19).
Paracellular Pathway
The paracellular pathway is a diffusion process that occurs
between 2 cells. This pathway is limited to small hydrophilic
molecules such as cimetidine, ranitidine, famotidine (46,47)
and furosemide (48), which are hypothesised to be absorbed
via the paracellular pathway in the intestinal track, due to the
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aqueous surroundings of the cells (49). However, due to the
presence of tight-junctions between two cerebral endothelial
cells, this route is extremely limited and nearly non-existent
at the BBB, although under some pathological conditions,
tight junctions and adherens junctions between endothelial
cells may be altered. This alteration enables leakage, which
can allow passage of plasma proteins, fluids or immune cells
into the brain (12,19,50–55). The selectivity of this route is
limited to either size or shape features.
Transcellular Pathway
Complex tight junctions force therapeutic molecules to fol-
low a transcellular pathway through the BBB rather than the
paracellular pathway as in most endothelia (19).
Passive Diffusion at the BBB
Passive diffusion is one of the most straightforward mecha-
nisms of permeation. This process requires a concentration
gradient but no energy and no specific protein carriers.
Diffusion requires physicochemical interactions between
the compound and the membrane that must be crossed
(43,44). Moreover, because there is no specific binding site,
passive transport is not affected by stereochemistry and there
is no saturation and no possible inhibition of the diffusion
process (56). These observations indicate that passive diffu-
sion is concentration-independent: the process occurs till
equilibrium between the blood and the brain.
Passive diffusion through the BBB is highly affected by
lipophilicity and the size of the compound (57–59). It was
demonstrated that compounds with a molecular weight
greater than 500–600 Da poorly permeated the BBB
(60,61). However, when combined with good lipid solubility,
molecules with molecular weights greater than 500 Da have
interesting BBB permeability characteristics (62). Similarly,
the lipophilicity of compounds should be high enough to
allow for good affinity with lipidic membranes, but the
lipophilicity should not be too high so as to avoid trapping
of the compound in the membrane and bioaccumulation. By
contrast, due to the hydrophobic nature of the membrane,
ionisation will greatly impact diffusion because ionised com-
pounds are highly hydrophilic and therefore have poor in-
teractions with the membrane (63).
Carrier-Mediated Transport at the BBB
A certain number of uptake or efflux proteins are expressed
at the BBB. These transporters are present on the luminal
and abluminal membranes of the endothelium and regulate
the entry of their specific substrates (19,64). Uptake proteins
transport molecules from the blood to the brain. These
transport systems allow the permeation of essential cerebral
nutrients, such as glucose or amino acids, and either limit or
prevent the passage of undesired or potentially toxic mole-
cules. By contrast, efflux proteins, such as P-glycoproteins (P-
gp/ABCB1), multidrug-resistance multidrug resistance asso-
ciated proteins (MRP) or the breast cancer resistant protein
(BCRP) (65), excrete their substrates out of the brain by
pumping the substrates into the blood stream. At the BBB,
P-gp/ABCB1 are highly expressed and a certain number of
NCEs are substrates for this protein (56).
Carrier-Mediated Uptake. Carrier-mediated transport can be
either active or facilitated. When the transport of a substrate
needs either direct energy which requires ATP binding and
hydrolysis to mediate the primary active transport process,
such as transporters of the ABC superfamily, or indirect
energy, which is driven by ion gradients that result from
ATP-dependent primary transport, such as many trans-
porters of the SCL superfamily, it is active carrier-mediated
transport, whereas when transport requires only a concen-
tration gradient and a transporter protein, it is facilitated
carrier-mediated transport. Both types of transport are sat-
urable, competitive and stereospecific (56). Moreover, these
types of transport imply a specific interaction between the
carrier proteins and the substrate.
Some examples of transporters are the glucose transporter
(GLUT-1), the monocarboxylic acid transporter (MCT1),
the large neutral amino-acid transporter (LAT1) and the
organic anion transporters (OATP) (32,66). Specific trans-
porters are also present for small ions, such as Na+, K+ or
Cl−, in both the blood to brain and brain to blood directions.
These ion transporters maintain brain homeostasis because
ionic disequilibrium between the blood and brain can have
serious effects, such as brain oedema.
Efflux Transport. Efflux transport is an energy-dependant,
active process, which pumps xenobiotics and metabolites
out of the brain into the blood stream. The most well-
known and studied efflux proteins belong to the ATP bind-
ing cassette (ABC) family, including the P-glycoproteins (P-
gp/ABCB1), which are encoded by the multidrug resistance
gene 1 (MDR1/ABCB1), the multidrug resistance associated
protein (MRP) and the breast cancer resistance proteins
(BCRP). These active transport processes are essential for
brain protection because they prevent the cerebral penetra-
tion of potentially harmful drugs and also excrete waste
products and metabolites. The expression of most efflux
proteins is regulated by astrocytes or pericytes (67).
Trans- and Endocytosis Mechanisms
Brain penetration is not strictly limited to small lipophilic
molecules or compounds shuttled by uptake proteins. Larger
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molecules, such as peptides, proteins or even viruses,
which are too large for a carrier-mediated process, can
also penetrate the BBB via the few pinocytic vesicles that are
present in endothelial cells. These large molecules can be
transported either by receptor-mediated transcytosis (RMT),
adsorptive-mediated transcytosis (AMT) (10) or fluid phase
endocytosis (32).
During RMT, the ligand specifically binds to the receptor
protein and is transported through the cell. The best
characterised and utilised RMT protein is most likely the
transferrin receptor, which has also been extensively studied
for the delivery of immunoliposomes. Other well-known
receptors include the low-density lipoprotein (LDL) receptor
and the insulin receptor (32).
During AMT, a non-specific interaction occurs between the
solute and the surface protein. Peptides, glycopeptides, glyco-
proteins, and viruses are transported by this pathway (32).
During a fluid phase endocytosis event, there is no contact
between the solute and the protein. The substrate is situated
close to the membrane, which deforms and encircles both the
solute and some extracellular fluid and transports the entire
vesicle to the abluminal side. Lucifer yellow is transported in
this manner (32).
STRATEGIES FOR IMPROVING BRAIN
PENETRATION
The BBB is a serious obstacle for the treatment of neurode-
generative diseases that require CNS action (43). Because of
its physical organisation, the BBB prevents the passage of
many drugs that target the CNS. Therefore, even if a poten-
tial drug has potent activity against its target, it may not be
able to cross the BBB and will most likely be discarded
during the drug development process. Moreover, metabolic
features of the BBB may also prevent a CNS active drug
from crossing the endothelial membrane because the thera-
peutic efficacy of the drug can be either inactivated or
decreased by enzymes at the BBB. To circumvent the BBB
and allow an active CNS compound to reach its target, many
strategies exist, which may be either invasive or non-invasive
with respect to the BBB.
Invasive Techniques
Direct Injection into the Cerebrospinal Fluid
Direct injection of drugs into the cerebrospinal fluid was the
first strategy used to circumvent the BBB, primarily to target
brain tumours. This technique is not very efficient because
there is a poor diffusion between the cerebrospinal fluid and
the brain and it is quite invasive (68). Nau et al. demonstrated
a 3-fold increase in the mortality of infants with Gram-
negative meningitis treated with an intraventricular injection
of aminoglycosides combined with intravenous injections of
antibiotics compared to intravenous injection of antibiotics
alone (68).
Therapeutic Opening of the BBB
Therapeutic opening of the BBB is a reversible process.
Because of specif ic molecules which generate a
hyperosmolar environment, the BBB loses its barrier prop-
erties, thus enabling passage of the therapeutics into the
brain before the BBB regains its functions. A transient brain
opening is generally obtained by intra-carotid injection of
mannitol or alkyl glycerol, which creates hyperosmolar con-
ditions on the systemic circulation side of the BBB and causes
a reversible shrinkage of the endothelial cells and a loss of
adherens and junctional proteins, leading to a paracellular
opening between endothelial cells (69,70). However,
depending on the mediator used to momentarily disrupt
the BBB, an increase in transcellular permeability can also
occur, such as with tumour necrosis factor α, which leads to
the permeation of opportunistic toxic compounds.
Moreover, the duration of the opening of the BBB will
depend on the mediator used. Histamine provides a rapid
and temporary opening, whereas thrombin causes drastic
modifications of the endothelial cytoskeleton resulting in
prolonged opening of the BBB with difficulties in returning
to the basal state (51).
This difficult strategy must be handled with care and
vigilantly monitored to prevent damage to the brain paren-
chyma and oedema, which may be fatal. However, when
performed properly, therapeutic opening of the BBB allows
for the delivery of active drugs into the CNS, which would
not otherwise reach the brain. This strategy is primarily used
for the treatment of brain tumours or life-threatening dis-
eases that have not been cured with less invasive treatments.
Non-Invasive Techniques
Brain penetration can be improved either using an alterna-
tive administration route, inhibiting efflux transporters,
chemically modifying or encapsulating the active compound.
The Nose-to-Brain Route
To circumvent the BBB and enter the brain parenchyma,
alternative strategies for drug delivery, such as the nose-to-
brain route, are useful. In the nose-to-brain pathway, the
therapeutic compound can be directly transported to the
brain by absorption in the nasal mucosa and transport via
the olfactory routes (71,72). Therefore, localisation of the
olfactory route close to a brain region that is exempt of BBB
allows for the circumvention of the barrier, which allows the
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drug to reach the CNS (73). This route has been evaluated
for the permeation of cocaine (74), as well as formulations
such as the alprazolam-loaded solid lipid nanoparticles (75)
or even neuropeptides (76). This strategy suffers primarily
from poor bioavailability, which ranges from 0.01% to 0.1%
(72).
Inhibition of Efflux Transporters
The presence of numerous efflux transporters at the BBB
prevents the entry of many CNS active compounds into the
brain. In HIV treatment, the most efficient drugs, such as
abacavir and efavirenz, are substrates of the ABC trans-
porters. Therefore, an interesting strategy is to inhibit efflux
transporter activity and saturate these transporters with sub-
strates that have higher affinity than the drug (77). This
strategy is efficient in HIV multi-therapy and improves the
intracerebral concentration of HIV protease inhibitors (33).
However, this strategy may have several drawbacks because
inhibition of efflux transporters will allow the penetration of
other xenobiotics, which may be potentially toxic in the
CNS. Therefore, adverse side effects may occur using this
strategy.
Use of Prodrugs
Pharmacology-based strategies are methods to either enhance
the lipophilicity of a drug candidate to favour its passive
permeation (78) or to mask the specific site recognised by
efflux transporters. The primary goal of this strategy is to
promote the permeation of compounds that have either low
uptake or are substrates of efflux transporters in their native
form. The addition of moieties to the drug, which are linked
by covalent reversible bonds, allows for the physicochemical
modification of the active compounds to cross the BBB. For
example, dopamine, a treatment for Parkinson’s disease, can-
not cross the BBB and enter the central nervous system where
its target is located. Therefore, carbonylation of dopamine
allows for the active transport of the inactive prodrug form
through the BBB. After the prodrug has entered the brain,
DOPA decarboxylase activates L-Dopa into active dopamine.
This strategy also permits the creation of a drug-reservoir,
depending on the rate of liberation of the native active com-
pound. This approach is, therefore, an asset for patient com-
pliance. However, chemical modification of the native active
drug may decrease its activity or bioavailability.
The Trojan Horses or the BBB Shuttles
The concept of a Trojan horse consists of coupling the drug
of interest, which cannot penetrate the BBB, to a compound,
such as a molecule, peptide, or transferrin, that crosses the
BBB via an active process uptake transporter, such as the
glucose transporter (GLUT-1) or transferrin receptor. The
BBB-penetrating moiety is recognised by the specific recep-
tor, leading to transport of the entire molecule, including the
drug (78). An extension of this concept was proposed by
Malakoutikhah and co-workers (79) who designed peptidic
Trojan horses that were able to cross the BBB via passive
diffusion. These compounds were defined as BBB shuttles.
The challenge of both Trojan horses and BBB shuttles is to
then liberate the active drug from the vector.
Drug Delivery with Nanocarriers
Liposomes, polymeric nanoparticles, solid lipid nanoparticles
and micelles are all nanocarriers and have garnered great
interest in recent pharmaceutical research. Because of the
incorporation of a drug into the inside core of the nanocarrier,
the drug bioavailability, physicochemistry and pharmacoki-
netics of the drug are changed (80,81). In pharmaceutical
research, a well-known problem is the discovery and develop-
ment of highly potent lead compounds, which are then found
to be either insoluble or poorly soluble. In most cases, either
the molecule will be discarded from the drug development
process, or a ligand strategy will be used to enhance the
solubility of the potential drug, with the risk of decreasing its
potency.
Drug delivery is a method of bypassing poor solubility,
poor permeability or poor bioavailability by incorporating
the compound of interest into either phospholipidic, poly-
meric or inorganic vesicles (82).
Liposomes consist of a phospholipid bilayer; therefore,
they allow for the incorporation of either hydrophilic mole-
cules, on the inside core, or lipophilic molecules, inside the
bilayer (82). These liposomes are extensively studied and
highly promising nanocarriers, particularly for cancer ther-
apy. Caelyx®, a pegylated liposomal formulation of doxo-
rubicin that targets breast cancer cells, is a good representa-
tive of the success of these formulations (83,84).
Three generations of liposomes have now been devel-
oped. The first generation consists only of a vesicle formed
by a phospholipid bilayer. These types of liposomes are
rapidly recognised by the reticuloendothelial system and
eliminated. Therefore, their efficacy is very limited and not
applicable for pharmaceutical purposes. The second gener-
ation of liposomes is surrounded by polyethylene glycol,
which is covalently linked to the outer part of the vesicle.
These pegylated liposomes have a longer circulation time in
the body because PEG is not recognised as a foreign body by
the immune system. The third generation of liposomes is the
most potent generation of liposomes. These liposomes con-
sist of the same pegylated liposomes as the second-generation
liposomes but are functionalised with specific moieties, such
as monoclonal antibodies, added to the PEG chain.
Therefore, the modified liposome is recognised by the
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antibody-specific receptor and may be taken up by the cell.
This strategy allows for specific targeting of cells. For exam-
ple, immunoliposomes, grafted with OX26 monoclonal an-
tibody are able to recognize transferrin receptor at the BBB,
which transport it through the a rat BBB model via endocy-
tosis (85). Up to now, many immune-conjugated
nanocarriers are on clinical phases such as doxorubicin,
anti-REH-2 (86), but none has launched the market yet.
Future years will probably disclose numerous new formu-
lations aiming at treating CNS pathologies.
The major drawback of liposomes is their poor stability,
which is due to their tendency to aggregate and their sensi-
tivity to oxidation and hydrolysis. Some of these problems
can be reduced by formulation strategies, such as the addi-
tion of α-tocopherol to decrease oxidation (87). Other re-
searchers have formulated liposomes as proliposomes, a dry
granular product, which disperses to form multi-lamellar
vesicles upon the addition of water (88).
Nanoparticles as drug carriers have also been extensively
studied recently. Their uptake into the brain is hypothesised
to occur via receptor-mediated endocytosis (89,90). Because
unmodified nanoparticles have been shown to be rapidly
cleared by the reticuloendothelial system, within 5 min in a
mouse model, surfactants or covalent binding of polyethyl-
ene glycol on the polymeric core led to a prolonged circula-
tion time and improved bioavailability (91). Only a few
nanoparticle formulations of drugs are currently on the
market (92), such as Rapamune®, an immunosuppres-
sant drug. Promising results have been obtained in
preclinical studies of a glioblastoma rat model, using
doxorubicin-incorporated nanoparticles; however, no
CNS-targeting nanoparticles are currently available in
the market. Nanoparticles can either be polymeric, li-
pidic or inorganic. The safety profile of these vesicles is
controversial, and much research is necessary to fully
describe the mode of excretion, the possible accumula-
tion of particles in organs and the side effects caused by
these nanoparticles.
METHODS TO ASSESS BBB PERMEABILITY
INFORMATION IN DRUG RESEARCH
In Silico Models That Predict BBB Permeability
In silico models are used during the early stages of the drug
discovery process when thousands of compounds must be
screened for either interactions with a specific target or for
the appropriate physicochemical properties. For example,
Lombardo et al. (93) succeeded in predicting the blood–brain
partitioning of compounds (log BB) using the calculated
solvation free energy. Others correlated log BB with a com-
bination of the molar refraction, solute polarisability,
hydrogen bond donor or acceptor capacity and molecular
volume (94,95). In silico strategies can filter large databases to
preselect compounds of interest and can predict whether a
compound will be prone to BBB penetration or not (96).
These computational strategies can decrease the number of
molecules to only few hit compounds, which are then tested
with in vitro models to determine the pharmacokinetics and
mechanism of action of the drug.
In silico models combine the measured brain penetration
information that is available in the literature with molecular
properties to build an algorithm that can predict BBB per-
meability. Using partial least squares regression, multiple
regression analysis or neural networks, in silico models can
generate ponderated regressions consisting of different phys-
icochemical properties, such as the lipophilicity (log P), stan-
dard free energy, H-bond donating capacity, H-bond
accepting capacity, and molecular weight of the drug.
In practice, the initial data, which are obtained from
libraries, are divided into 2 subtest sets, a training set, which
is used to build the algorithm, and a test set, which allows for
determination of the predictive ability of the algorithm. The
experimental permeabilities of the test set are statistically
compared to the predicted values that are generated by the
algorithm to determine this predictive power (96). The vari-
ety of algorithms that are able to build a predictive model is
huge because many descriptors may be used to generate an
equation. Some examples of in silico models to predict log BB
are listed in a review of Abraham (96). In general, the chosen
descriptors are related to the size of the molecules and their
physicochemical properties. As Abraham noted, an increase
in size-related descriptors leads to an increased log BB
(higher brain penetration), whereas an increase in the
polarity-related descriptors leads to a decreased log BB.
This characteristic is linked to the physicochemistry of both
compartments, with the brain being more lipophilic than the
blood. Moreover, Didziapetris et al. (97) suggested that acids
with a pKa>4, containing greater than 8 oxygen and nitro-
gen atoms and a molecular weight greater than 400 Da were
likely to be substrates of efflux proteins.
A major issue resulting from in silico models is the reliabil-
ity of the chosen training sets and test sets. It is difficult to
obtain experimental data that are homogeneous in terms of
the experimental design, such as whether the perfusion was
performed with whole blood, plasma or saline solutions, the
reliability of descriptors, such as whether there was
ionisation, and the experimental know-how. The ideal situ-
ation would be to obtain the experimental data from the
same laboratory, under the same conditions; however, that
situation is utopic because the amount of data would be
either too low to build the model or not diverse enough.
Therefore, attention should be paid when handling in silico-
predicted data, and the user must also understand how the
model was built.
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In Vitro Models for Prediction of BBB Permeability
Different approaches have been proposed for the in vitro
evaluation of whether a new chemical entity can cross
the BBB. Significant differences exist from one method
to another in terms of complexity and, consequently,
cost and information obtained (Fig. 1). In this section,
in vitro methods for predicting BBB permeability are
ordered according to increasing complexity.
Immobilised Artificial Membrane
Lipophilicity (log P or log Poctanol/water) has long been
reported to be a major parameter that influences CNS
activity and the blood/brain concentration ratio (log BB)
(98,99). Because of its lipophilic feature, n-octanol was
widely used for pharmacokinetic predictions. The small polar
head of n-octanol and its hydrophobic carbonylated chain
make it appear similar to phospholipidic membranes.
However, the relationship between log P and log BB
is not strong enough for the needs of CNS researchers.
Therefore, immobilised artificial membranes (IAMs)
were proposed as an alternative to log P predicted with
shake flask or liquid chromatography (100–103).
Modified HPLC columns were prepared in which phos-
pholipids were covalently bound to the silica (99).
Experiments showed a linear relationship between the
retention factors on IAMs and the partition between an
aqueous phase and liposomes (104). Moreover, IAM
chromatographic retention factors were shown to gener-
ate information on membrane permeability (105). In
some cases, these types of systems have shown reason-
able results for permeability prediction, even if the
retention time on the column does not reflect transport
across the membrane (106,107). However, there are
some limitations in terms of retention times for lipophil-
ic compounds and stationary phase stability. Recently,
short IAM columns appeared on the market. These
columns (1–3 cm versus 10–12 cm) allow greater
throughput but do not really offer any improvements
in terms of reliability, and this approach is not widely
used in drug discovery.
PAMPA Models
The parallel artificial membrane permeability assay (PAMPA)
is a relatively recent technique developed in 1998 by Kansy
et al. (108) to rapidly predict passive permeability through the
gastrointestinal tract with high throughput efficiency. In this
technique, a donor and an acceptor compartments are sepa-
rated by a filter supporting a liquid artificial membrane. The
drug to be tested, placed in the donor compartment, can then
permeate between the donor and the acceptor compartments
through the artificial membrane. The assay is performed in
96-well plates and thus enables high throughput screening.
The permeability coefficient is then determined in a
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straightforward manner with the permeability equation de-
scribed by Avdeef (63). The artificial membrane that was
originally made of phospholipids (56,109) can also be as simple
as an organic solvent (110) or a mixture of solvents (111).
PAMPA is gaining interest in the early drug discovery
process because it is possible to rapidly obtain the straightfor-
ward permeabilities of numerous compounds, it is cost effi-
cient, it has high inter- and intra-laboratory reproducibility
and it can target different biological membranes. The major
drawback of the PAMPA technique is that it can only predict
passive diffusion and is therefore unable to generate a full
description of the permeability process at the BBB. It is well-
known that numerous transporters and enzymes are expressed
at the BBB level, greatly modifying the pharmacokinetics of
the substrates of these transporters, such as verapamil, a P-
gp/ABAB1 substrate. Therefore, for these specific com-
pounds, PAMPA generates only a portion of the information
regarding passive transcellular transport. PAMPA should not
be used for compound selection purposes particularly for BBB
penetration, because of the numerous transporters and meta-
bolic enzymes that are present at the BBB. P-gp/ABCB1
substrates more permeate in a PAMPA model compared to
in vivo or in vitro cellular models.
Phospholipid-Based Membrane. Developed in 2003 by Li Di
et al. (112), PAMPA-BBB has shown good prediction of BBB
penetration for CNS classes of drugs. The drugs are described
as CNS+ for compounds that have a high penetration
through the BBB, CNS- for compounds that have a low
permeability or are unable to penetrate the BBB, and
CNS+/− for compounds with a medium permeability coeffi-
cient. In this assay, the artificial membrane is composed of
porcine polar brain lipid extracts and the incubation last for
18 h. A quantitative analysis correlating the permeability co-
efficients generated with PAMPA-BBB and in situ brain per-
fusion gave a poor correlation coefficient of r2=0.47 (113,114)
for a test set of 37 compounds. However, for 30 test com-
pounds, this assay succeeded in predicting 25 compounds with
the correct class of permeability, either CNS+ or CNS-. The
only negative outlier was actively transported, whereas the 4
false positives were either substrates of efflux pumps or
metabolised in vivo. One weak point of this assay is that it is
performed under unstirred conditions, which maximises the
unstirred water layer (UWL). UWL is a stagnant water layer
at the two sides of the artificial membrane that has a distinct
boundary with bulk water (63). This layer can highly modify
the permeation of compounds, in particular hydrophobic
compounds, because passage through the UWL is governed
by diffusion laws. Because of the blood flow and the very small
size of the cerebral capillary, the in vivo UWL is nearly null.
However, this is not the case for the in vitroUWL, particularly
for the unstirred in vitro assay in which the UWL can be as
thick as 1.5 to 2.5 mm (115).
Solvent-Based PAMPA. HDC-NPOE PAMPA is a high
throughput screening method that has recently been devel-
oped to predict the passive transendothelial permeability
through the BBB and is currently under study (116). The
innovation of this PAMPA technique is in the use of non-
biological materials for the membrane, which allows for
better reproducibility. In this new PAMPA model, the arti-
ficial membrane is composed of 75% hexadecane and 25%
o-nitrophenyl octyl ether and incubation lasts for 7 h, en-
abling permeability determination within the working day.
The experimental permeabilities determined by this new
method demonstrated a good relationship with the perme-
abilities generated by a well-established cellular model
BBCEC model from Cecchelli et al. (27,117) (r2=0.92;
N=13) and the PAMPA-BBB (112) (r2=0.80: N=14).
Furthermore, a correlation was also established with an
in vivo model of rat brain perfusion (118) (r2=0.81; N=6)
but only with a reduced number of compounds.
Compatibility of PAMPA with New Drug Delivery Strategies. In
2009, Han et al. (109) used PAMPA to determine the intes-
tinal permeation of ginsenoside, a hydrophilic molecule with
very low membrane permeation, that was incorporated into
a water-in-oil microemulsion. The objective was to obtain
information on the mechanism of permeability of this carrier
system. The original protocol of Kansy (108) using a
phospholipidic-based membrane was used. Han et al. dem-
onstrated an increased permeation of ginsenoside due to
good permeation of the water-in-oil microemulsion through
the PAMPA membrane. These results were corroborated by
rat everted intestinal sac studies.
In 2007, Mathot et al. (119) used the phospholipidic
PAMPA developed by Kansy (120) and commercialised by
pION Inc. to evaluate the passive diffusion of polymeric
micelles formed from polymeric surfactants through the gas-
trointestinal tract. They had already shown in the Caco-2
model that the polymers were able to cross the cells but did
not know the possible mechanism of passage. Analysis of the
acceptor compartment demonstrated the passage of the
polymeric micelles through the lipid artificial membrane
with a permeability coefficient of 1.0×10−6 cm.s−1. To the
best of our knowledge, no current study has evaluated the
prediction of BBB permeation of these materials using the
solvent-based PAMPA technique. However, the results
obtained for the phospholipid-based PAMPA models for gas-
trointestinal tract passive transport predictions indicate that
these models can be used to obtain information on the per-
meation of chemicals loaded in specific carriers. However,
testing a new material on PAMPA is not obvious and requires
particular attention regarding the reciprocal impact of carriers
on the artificial membrane and vice versa. Therefore, prelimi-
nary tests must be performed before the permeability coeffi-
cients obtained from PAMPA tests can be interpreted.
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Cell Culture Models
Cellular models that predict BBB permeability are exten-
sively used during the early drug discovery process. A large
panel of cellular models exists that differ in origin, the type of
expressed transporters, the tightness of the tight junctions
and affiliation with a primary or immortalised cell line.
These factors greatly influence the reproducibility of the
permeability experiments and the capacity of these models
to predict in vivo BBB permeability. Therefore, all cellular
models are different and generate specific information on
permeability through the BBB. Furthermore, none of the
existing cellular models can fully predict the pharmacokinet-
ic behaviour of drugs in vivo.
The main advantages of cellular models are the through-
put rate, which allows for the evaluation of a reasonable
number of compounds even if this rate is only moderate.
Additionally, cellular models have the capacity to evaluate
transport mechanisms, which depends on the type of
expressed transporters and the possible evaluation of metab-
olism and cytotoxicity. Furthermore, pathological conditions
can be investigated choosing an appropriate model (121). By
contrast, homogeneity and reproducibility are difficult to
obtain with cellular models, although these problems may
be limited with the development of immortalised cell lines
and standardised protocols.
To differentiate the wide variety of cellular models in
existence since the 1970s, the following BBB parameters
must be considered: the transendothelial electrical resistance
(TEER), which indicates the tightness of transendothelial
tight junctions and, therefore, restriction of the paracellular
pathway; the endothelial permeability coefficient for
paracellular markers such as sucrose, which indicates the
integrity of the membrane (66); the expression of specific
BBB transporters, such as the carrier-mediated transporters,
including glucose transporters (GLUT1), monocarboxylic
acid transporter (MCT1), large amino-acid transporters
(LAT1), and cationic acid transporters (CAT); the active
efflux transporters, including the ATP binding cassette
(ABC) gene family or solute carrier (SLC) gene family
(122); and the presence of BBB markers, such as factor
VIII, γ-glutamyl transpeptidase (γ-GT), alkaline phospha-
tase (ALP) and monoamine oxidase (MAO) (123). Because
the in vivo TEER of brain microvessels is approximately
1,000–2,000Ω.cm2 (124,125) and the permeation of sucrose
can be as low as 0.03×10−6 cm.s−1 (126), the ideal cellular
model should provide values as close as possible to the known
values for these parameters.
Primary Cultures. Cell biology research for the development
of in vitro models of the human BBB began with primary
bovine (40,127–137) and porcine (138–142) cultures
(Table I) because the brain size of these animals is large;
leading to a high yield of cells per brain. However, rat
(143–145), murine (146,147) and human (148–152) cell cul-
ture systems have also been developed. Compared to porcine
or bovine cells, rat and mouse endothelial cells generate
models with fewer BBB characteristics, such as a TEER
value between 9 and 150Ω.cm2 and a Pe (sucrose) of approx-
imately 7.5×10−6 cm.s−1 (Table I). Therefore, mouse brain
endothelial cells are difficult to culture and lead to poor
development of the endothelium (67). Additionally, because
the number of cells per brain is limited, the batches of cells
are always different even when the same protocol is used for
extracting and seeding cells. This variability causes repro-
ducibility issues because the cells used for permeability de-
terminations are not the same from one day to the next. This
is one reason why researchers have very little interest in using
mouse primary cells for BBB permeability studies even if the
best murine models can compete with some of the bovine
models (144,153).
Bovine endothelial cells were the first in vitro BBB model
and were developed by Bowman et al. as soon as 1983 (130).
However, one of the primary bovine models expressing
sufficient TEER for the prediction of BBB penetration was
developed by Zenker et al. in 2003 (154). In this model, the
TEER value reached 1,350Ω.cm2, but values this high were
rare and were dependent on the batch of cells. Furthermore,
no paracellular permeability verification was performed,
which makes an appropriate discussion of this model
difficult. In general, the average TEER value generated
with primary bovine endothelial cells is 150–200Ω.cm2,
which is far from the in vivo TEER value of 1,000Ω.cm2
(40,127–137).
Porcine models display the best barrier properties
(Table I). These models exhibit high TEER values ranging
from 70 to 1,800Ω.cm2 depending on the culture conditions
and medium supplementation. Porcine models also have a
low paracellular permeation of sucrose, with values ranging
between 0.2 and 25×10−6 cm.s−1 (138–142,155–162).
Moreover, specific transporters, such as GLUT-1 or acety-
lated LDL, and brain enzymes, such as the γ-GT or
ALP, display efficient metabolic activity (142) (Table I).
The most efficient cellular model of the BBB was de-
veloped by Franke et al. (159,163,164) who grew prima-
ry porcine brain microcapillary endothelial cells in
serum-free medium containing hydrocortisone. The re-
sult of this treatment was a monolayer of endothelial
cells with very tight junctions, TEER values reaching
1,500Ω.cm2 with an average of 700±100Ω.cm2, and a
sucrose permeation as low as 0.3×10−7 cm.s−1. Further
evaluations indicated that this model expressed several
ATP-binding cassette (ABC) transporters, nutrient trans-
porters and specific BBB receptors (165). However, this
model has not been used for any further permeability
determinations.
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Human brain cells are the gold standard for a human BBB
in vitro model. However, for ethical reasons, the availability of
this type of cell is very limited. The cells are generally obtained
from biopsies of epileptic patients, and the number of cells
obtained is very low. Rubin et al. and Bernas et al. developed
primary human endothelial cell models with TEER values of
339±107Ω.cm2 and >1,000Ω.cm2, respectively (40,166). No
paracellular permeability was mentioned in these models, but
the model developed by Bernas et al. was used in several
studies to evaluate the effect of chemicals, such as cannabinoid
receptor agonists, on the barrier function of BBB (167).
Studies of these human models are limited and have instead
focused on the generation of immortalised human cell lines,
which should decrease the inter-individual, race, age and
gender variations and increase the quality and reproducibility
of the results obtained with human models.
Primary cell cultures may provide interesting information
on human BBB permeability, but these models and culture
conditions are not straightforward. Homogeneity and repro-
ducibility of these models is not guaranteed because an
animal brain cannot generate an infinite number of identical
cells. Therefore, the variability of these models is due to
inter-laboratory and inter-individual factors, among others,
and leads to large standard deviations. Finally, primary
monocultures of brain endothelial cells were shown to rap-
idly lose their BBB properties, including tight junctions and
specific transporters (168).
Immortalised Cell Lines. To limit the drawbacks related to the
handling of primary cells, researchers have immortalised their
cultures to make cell lines. Immortalisation is generally
achieved with either gene or virus transfection (148,169–171),
such as the SV40 large T-gene antigen (67) or the E1A adeno-
virus gene (172) in the RBE4 model.
Few monoculture models of immortalised cell lines have
been developed (Table I), however, bovine (173), human
(148,150,174–181) mouse (182,183) and rat (172,183–188)
endothelial cell lines have been established and tested for
BBB properties. The model with the best BBB properties is a
human brain endothelial cell line (150), with TEER values
ranging from 300 to 400Ω.cm2; however, no sucrose perme-
ation has been achieved, but inulin transport studies show
low paracellular permeation. In 2005, Weksler et al. devel-
oped a model based in human cerebral cells: the
hCMEC/D3 cell line, which displayed a TEER value below
40Ω.cm2 and a sucrose permeation of 27.10−6 cm.s−1
(174,189). Furthermore, many drug transporters, including
most of the ABCB, ABCC and ABCG families found in the
human BBB in vivo have been detected in the hCMEC/D3
cell line. Because of the existing BBB properties and its
human origin, the hCMEC/D3 model has been used for
many kinetic, pharmacological and permeability studies
(190–193).
In order to understand the predictive ability of primary
cells and immortalized cell line, Steiner et al. (11) compared
primary mouse brain microvascular endothelial cells with
immortalised mouse brain endothelial cell lines and deter-
mined that the two types of endothelial cells exhibited dif-
ferent cytoskeletal morphologies. Moreover, the protein
occludin, which plays a role in tight junction formation,
was localised in the primary endothelial cells but not in the
cell line, indicating a divergence in the junctional organisa-
tion. This deviation leads to tighter junctions in the primary
endothelial cells compared to the immortalised endothelial
cells. Therefore, monocultures of immortalised cells are of
limited interest for the prediction of BBB permeability, ex-
cept the immortalised cell culture models derived from hu-
man cell lines.
Cocultures. Following the development of a variety of mono-
culture models and the determination that cerebral endothelial
cells alone, whatever their origin, do not express the appropri-
ate BBB properties and also lose their specific characteristics
when isolated from their environment (27,145), cocultures
became attractive models. In the human brain, there is con-
stant communication between endothelial cells and other types
of cerebral cells comprising the neurovascular unit, such as
astrocytes, pericytes, neuroglia, and neurons (60,194). The
action of surrounding cerebral cells on endothelial cells creates
BBB properties and induces the production of junctional pro-
teins and the expression of all the enzymes and transporters at
the BBB (8,9,14,19,67,71,195). Moreover, it was shown that
astrocytes were able to reinduce BBB properties (196).
Megard et al. (152) noted several interesting observations
in their research on human brain endothelial cells cocultured
with human astrocytes.
The resulting coculture exhibited specific barrier proper-
ties, such as a TEER value of 260±130Ω.cm2 (endothelial
cells alone: 61±2Ω.cm2 and astrocytes alone: 37±5Ω.cm2)
and a sucrose permeation of 17±3.10−6 cm.s−1. To validate
this BBB model, the authors selected the lipophilicity of a
compound as a good indicator of BBB permeability. They
demonstrated a good relationship between the in vitro BBB
permeability of this model that was corrected with the molec-
ular weight and the partition coefficients (r2=0.88). Using flow
cytometry and PCR, they showed that their model expressed
P-gp/ABCB1 mRNA. A permeability determination with
known P-gp/ABCB1 substrates, such as vincristine, verapamil
or vinblastine, revealed a higher permeability from the basal
to the apical compartments than from the apical to the basal
compartments, indicating an efficient efflux process. These
results underline the beneficial effect of cocultures on the
expression of specific BBB properties in vitro models. The
upregulation of P-gp/ABCB1 and the higher TEER value
in cocultures compared tomonocultures were also observed in
several other studies (9,154,184,195,197,198) (Table II).
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These cocultures can be established with either primary
cells or cell lines. As indicated in the review by Deli et al. (66),
many different cocultures have been developed but are usu-
ally established with endothelial cells and astrocytes from
various animals. When the BBB properties of these cocul-
tures were compared to the barrier properties of the corre-
sponding endothelial monoculture, the resulting TEER
values were generally improved, whereas the permeation of
a paracellular tracer was decreased. Consequently, the ex-
pression of tight junction proteins is upregulated under
coculture conditions, resulting in an improved in vitro BBB
model (197).
To determine the reason why BBB properties are
reinduced when endothelial cells are cocultured with astro-
cytes, Bénistant et al. (168) evaluated the fatty acid composi-
tion of bovine brain capillary endothelial cells either
monocultured or cocultured with rat astrocytes. They found
that the phospholipid profiles of the endothelial cells were
clearly different between the two culture conditions. The
most significant differences were observed for palmitic acid,
which was 13% of the total phospholipid proportion in the
monoculture vs. 20% in the coculture, and for linoleic acid,
which was 18% in the monoculture vs. 10% in the coculture.
Therefore, these results indicated that the presence of astro-
cytes when culturing endothelial cells can modify the fatty
acid composition of brain endothelial cells.
In 2009, Nakagawa et al. (194) established a coculture
model with three different types of cerebral cells, endothelial
cells, pericytes and astrocytes, to provide a more realistic
representation of the in vivo BBB. The pericytes were shown
to have a similar positive influence as astrocytes on the tight-
ness of the tight junctions (199). The TEER value of this triple
coculture reached 400Ω.cm2, with a permeation of
3×10−6 cm.s−1 for the non-permeant dye fluorescein.
Moreover, specific BBB transporters, such as P-gp/ABCB1,
glucose-transporter (GLUT1) and ABCC1, were expressed in
the brain endothelial cells (Table II).
The BBB model displaying the best barrier features was
developed by Dehouck et al. (27,39,121,197,200) and was
called the bovine brain capillary endothelial cells model
(BBCEC). This model, consisting of primary bovine endothe-
lial cells cultured on one side of the filter and rat glial cells on
the other side of the filter, exhibits high TEER values due to
the presence of complex tight junctions. The TEER values
range between 700 and 800Ω.cm2 (13), and the BBCEC
model displays a low sucrose permeation between 5.4 and
32×10−6 cm.s−1, a low rate of pinocytosis, the presence of P-
gp/ABCB1 and metabolic enzymes, such as γ-GT, MAO,
and the occurrence of LDL and transferrin receptors (27).
This combination of characteristics leads to interesting BBB
properties.
When correlating in vitro BBB data, which are corrected
by the molecular weight and a logarithmic function, with theTa
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corresponding BUI or in vivo BBB permeability, both of
which are also corrected, excellent relationships were ob-
served (r2=0.86) (121).
In conclusion, with regard to cellular models consisting of
cerebral cells, primary cell cocultures generate the best
models, although the reproducibility may not be optimal.
The upregulation of tight junction proteins under coculture
conditions allows for increased TEER values and decreased
paracellular transport, which are characteristics of the BBB.
The gold standard model would be a coculture of primary
human cells, but this requires a constant renewal of the
donor brain tissue, which causes ethical concerns.
Cell Lines of Non-Cerebral Origin
The Madin-Darby Canine Kidney Cell line (MDCK). MDCK
cells are cells of non-cerebral origin that are relatively easy to
grow and can be transfected with specific gene transporters,
particularly the MDR1 gene, which codes for polarised
expression of P-gp/ABCB1 (71). These transfected MDCK
cells can then be used for the MDR1-MDCK (I or II) assay.
MDCK cells can generate TEER values as high as 1,800–
2,200Ω.cm2 (201), indicating the existence of robust barrier
properties with high expression of tight junctional proteins.
Moreover, the in vitro-in vivo correlation obtained with this
model is better than some of the existing in vitro models with
cerebral cells, with r2=0.64 (123) or 0.72 (202) when passive
compounds are selected for the correlation, depending on
authors. However, in vitro/in vivo correlations with a diverse
set of compounds (including compounds being actively
transported or effluxed at the BBB) do not exhibit a signifi-
cant correlation (r2=0.40) (123). The greatest limitation of
these cells is the absence of transporter proteins other than P-
gp/ABCB1 and their different morphology compared to
endothelial cells because MDCK cells are epithelial cells
(71,203). Moreover, these cells are derived from dog kidney
cells (201). However, transfection of the MDR1 gene allows
for the determination of P-gp/ABCB1 substrates by measur-
ing the permeability on both sides of the membrane. Another
study conducted by Di Li et al. (114) did not generate an
in vitro-in vivo correlation comparing the in vitro MDR1-
MDCK permeation of a very diverse set of compounds with
permeations obtained from in situ brain perfusion (r2=0.007
(114)). This absence of correlation was most likely due to
saturation of the P-gp/ABCB1 in vivo. The concentrations
utilised for the in situ brain perfusion study were very high
compared to the Michaelis-Menten constants of the com-
pounds. These high concentrations lead to saturation of the
efflux transport and use of the predominantly passive diffu-
sion pathway, which overestimates the permeability in vitro.
Therefore, attention should be paid to the experimental
conditions when performing permeability assay with
saturable transport. Moreover, differences in membrane
characteristics, such as epithelial kidney cells for the
MDR1-MDCK assay and cerebral endothelial cells for the
in situ brain perfusion study, lead to a significant discrepancy
in the predicted BBB permeability. Moreover, the phospho-
lipid composition of both membranes is fundamentally dif-
ferent, with a higher proportion of cholesterol in the cerebral
membrane than the MDCK cells. This composition leads to
an increased fluidity of MDCK cells, which facilitates passive
permeability in this model.
Caco-2 Cells. Caco-2 cells are epithelial cells derived from a
human colon carcinoma and are extensively used in the
pharmaceutical industry to predict oral absorption through
the intestinal epithelium.Moreover, the Caco-2 model is also
used to predict BBB transport, even though the gastrointes-
tinal tract is fundamentally different from the BBB, but as
in vitro BBB models have evolved, the in vivo permeability
predicted by the Caco-2 model became less and less useful
(121,123,202). compared to other models. However, the
Caco-2 assay remains an efficient method of identifying sub-
strates of the P-gp/ABCB1 transporter from a set of test
compounds because of the overexpression of P-gp/ABCB1
in cancer cells. More recently, Ball et al. (204) developed a
physiologically based pharmacokinetics model to predict the
fraction of unbound drug reaching the brain. They succeeded
in generating an in vitro model that faithfully fits the in vivo
unbound brain concentration of morphine, which is effluxed
at the BBB, and oxycodone, which is taken up at the BBB.
The Kp,uu was determined in Caco-2 cells expressing the P-
gp/ABCB1 efflux transporters for morphine and in TR-
BBB13 cells, which enable active uptake, for oxycodone.
Both resulting distributions were corrected by a relative activ-
ity factor, which was estimated by a comparison between the
in vitro model predictions and the in vivo data in rats.
Adaptation of BBB Cell Models to New Delivery Strategies
Some models were used to obtain information on nanocarrier
transport across the BBB.
Nanoparticles. In 2006, the transcytosis of polyethylene
glycol-polylactide (PEG-PLA) nanoparticles across the BBB
was evaluated by Lu et al. using a rat syngeneic coculture of
brain capillary endothelial cells and astrocytes (205). The
fluorescent compound 6-coumarin was incorporated inside
these nanoparticles with a final size of 102.4±6.8 nm. After
transport study of the coumarin-loaded PEG-PLA
nanoparticles across the coculture, a permeation of
4.8×10−6 cm.s−1 was obtained. However, the permeation
of the paracellular marker sucrose was higher than the per-
meation of the nanoparticles. Therefore, either a
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paracellular route or a transcytosis process may have oc-
curred in this in vitro model.
Ragnaill et al. (206) later described the transport of 50 nm
silicium dioxide nanoparticles through the in vitro
hCMEC/D3 BBBmodel (174,189). They succeeded in show-
ing that nanoparticles were effectively taken up by the cells
with the membrane enveloping the nanoparticles. Moreover,
they also observed the nanoparticles in both the endosomes
and lysosomes and some on the basolateral side of the mem-
brane. Therefore, they suggested that the silicium dioxide
nanoparticles were endocytosed and that an exocytosis process
also occurred.
Liposomes. The hCMEC/D3 cell line was also used to study
the BBB penetration of an immunoliposome decorated with
OX-26, an anti-transferrin monoclonal antibody (193). The
objective of the study was to target the transferrin-receptor for
transport of the immunoliposome by a receptor-mediated
transcytosis process . The mean diameter of the
immunoliposomes was assessed with dynamic light scattering
and was less than 200 nm. They demonstrated that the
immunoliposomes were transported through the endothelial
monolayer by receptor-mediated endocytosis.
In vitro cellular models can therefore be used for the
permeability determination of more complex formulations,
such as nanocarriers. However, adaptation of the model may
not be straightforward because of the potential cell toxicity of
the carriers, and a full assessment of the validity of the models
is required before a discussion of the results, but promising
data regarding the distribution of nanocarriers are emerging.
Transport Across Isolated Brain Microvessels
Isolated brain microvessels are generally used to evaluate the
gene expression of specific transporters at the BBB (207), but
permeability experiments may also be conducted to identify
specific transporters. Fluorescent probes are tested in the
presence or absence of known substrates of the transporters.
A variation in the permeability indicates the presence of the
specific transporter that is being assessed (208,209). Miller
et al. used confocal microscopy to detect fluorescent xenobi-
otics, such as daunomycin and fluorescein labeled dextrans,
within the lumen of isolated brain microvessels (208). They
succeeded in demonstrating a concentrative, specific and
energy-driven transport process, indicating the expression
of specific active transporters in isolated brain capillaries.
Studies with specific substrates and immunostaining indicat-
ed that the active process was initiated by P-gp/ABCB1 and
Mrps. The P-gp expression in isolated brain capillaries was
corroborated by the studies of Durk et al. (209).
Transport across freshly isolated brain microvessels is a
good alternative to cell culture because it is less time
consuming; however, isolation of the brain microvessels re-
quires much skill and very clean manipulations to obtain
microvessels that are extremely pure. Moreover, reproduc-
ibility issues may be more important in this model than for
cellular models because fresh microvessels must be freshly
prepared for each experiment.
In Vivo Models
In vivomodels are the best models available to predict human
in vivo permeabilities because of the combination of all bio-
logical aspects in the same model, such as physiological
barriers, transporters, and metabolic pathways. However,
these models are expensive, time-consuming, require the
mastering of animal-based assays and often necessitate
radiolabelled compounds. These factors ensure that in vivo
models are used during the later stages of the drug discovery
process, just prior to clinical investigations, for a limited
number of lead compounds. Different in vivo models are
available, which allows for determination of the permeation
of the molecules tested and in particular the logarithm of the
BBB permeability-surface area (log PS) or the logarithm of
the brain to plasma ratio (log BB) (Table III). These models
include in situ brain perfusion, single carotid injection (brain
uptake index; BUI), intravenous injection and intracerebral
microdialysis (71). The log PS is considered the most relevant
indicator of BBB permeability because it measures the clear-
ance of a drug from the blood to the brain across the BBB
(210) and is not altered by either metabolism or protein
binding (114). The log PS is determined from the Kin, which
is the clearance out of the brain. This determination better
reflects BBB permeability..
Determination of the log BB requires several time point
measurements, which requires animals a t each time point
and is costly. Moreover, several factors, such as metabolism
and binding, interfere with brain penetration in the log BB
determination; therefore, log BB is not an accurate measure-
ment of BBB permeability.
The Intravenous Administration Technique
Intravenous administration is one of the less invasive and
most physiological methods of determining in vivo permeabil-
ity. In this technique, the buffer containing radiolabelled
solutes is injected inside a cannulated femoral vein or in the
tail vein of the rat. The plasma concentration of the products
is monitored for 10 s to several hours over various time
points. The pharmacokinetic parameter obtained is the area
under the curve of the drug concentration in the blood
between time 0 and the time of the decapitation (211).
Therefore, the measured permeability will include the effec-
tive permeability, which is influenced by protein binding and
metabolism. This technique has numerous advantages, such
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as the BBB remaining undisturbed and all transporters,
enzymes and junctional proteins remaining intact, which
enables metabolism. An entire pharmacokinetics profile
can therefore be obtained. Moreover, because the evaluation
can be performed for an extended period of time, both the
plasma and brain pharmacokinetics can be determined.
However, the study of specific influx transport is not possible
with this intravenous administration technique.
The Brain/Plasma Ratio
The brain/plasma ratio, established by Ohno et al. (212),
resulted in determination of the blood–brain distribution
coefficient (BB), which is defined as the ratio between the
concentration of the compound in the brain and in plasma.
Therefore, this approach may be misleading because the
partition parameter that is obtained is dependent on the
affinity of the tested drug for circulating proteins in the blood
stream (213). This method provides determination of the
drug partition between the plasma and brain but does not
provide a pharmacokinetic profile. Determination of the
brain/plasma ratio can be performed either at steady state
or at different time points and requires sacrificing the animal
and determining the concentration of the unbound drug in
both the brain homogenate and plasma.
A brain/plasma ratio ≥1 indicates that a compound is able
to cross the BBB, whereas a brain/plasma ratio <1 reveals a
poor distribution of the compound (213). However, due to
plasma protein binding, a brain/plasma ratio <1 may also
indicate a high affinity for circulating plasma proteins or an
affinity for efflux proteins, both of which limit permeation of
the compound through the barrier. Therefore, interpretation
of the brain/plasma ratio must be performed cautiously.
Young et al. (214) used the brain/plasma ratio to design
and select a CNS-active H2 histamine receptor antagonist.
More recently, Rohanova et al. used the brain/plasma ratio
to study the brain penetration of a new illegal drug p-
methoxymethamphetamine and its metabolites to better un-
derstand both the mode of action andas the toxicity profile of
these new drugs (215).
The Unbound Brain/Plasma Ratio: Kp,uu
To correct the errors that may be introduced by measurement
of the brain/plasma ratio, a recent tendency consist in deter-
mining the unbound brain to plasma ratio (Kp,uu). This param-
eter may be obtained directly by intracerebral microdialysis or
with a combination of in vivo and ex vivo techniques. The last
experiment is achieved measuring the quantity of drug that has
reached the entire brain in vivo combined with an estimation of
the unbound brain volume of distribution with ex vivo techniques
such as the brain slice uptake experiment. The determination of
Kp,uu provides a better indication of the distribution of the active
form of the drug. A Kp,uu that is greater than unity indicates the
presence of an active uptake process, whereas a Kp,uu less than
unity indicates the presence of an efflux process. A Kp,uu near
one indicates that the predominant pathway through the BBB is
a passive diffusion process (216).
Table III Summary of the In Vivo Techniques in Late Drug Discovery Research
In vivo techniques Characteristics Experimental data
Brain/plasma ratio Study of low to rapid penetrating compounds;
choice of variable exposure times; possible
metabolism, protein binding and active transport.
A partition coefficient between plasma (or blood)
and brain is generated. Be careful to misleading
caused by protein binding.
Brain uptake index Study of moderate to rapid penetrating compounds;
fast brain exposure (5 to 15 s between the
injection and the sacrifice of the animal); no
metabolism, no protein binding, no efflux transport.
log PS are generated. The extremely fast brain
exposure time leads to sensitivity problems,
due to very low concentration in the brain.
In situ brain perfusion Suitable for low to rapid penetrating compounds; fast
to long exposure times (5 s to 1 h); no metabolism,
no protein binding, possible transport.
Data similar as Brain uptake index is generated.
Sensitivity is much higher, thanks to a possible
long brain exposure time.
Intravenous administration technique Study of low to rapid penetrating compounds;
monitoring of the plasma concentration; existence
of in vivo metabolism, protein binding and transport.
A whole pharmacokinetics profile is generated,
on an intact BBB. This is the less ethically invasive
and the most physiological method.
Intracerebral microdialysis More appropriate for medium permeant compounds.
Drug monitoring of the unbound drug fraction after
the choice of the mode of administration; existence
of in vivo metabolism, protein binding and transport.
A whole pharmacokinetics profile is generated, but
BBB can be damaged due to surgery.
Monitoring is made on the same animal: decrease
the number of experimental animals, no deviation
due to variation in the origin, age, gender, weight
of the animal.
Imaging Visualisation of the distribution in the body. Appropriate
for medium to rapid penetrating compounds.
Non-invasive technique, which can be employed
in humans. Existence of sensitivity issues, require
expensive equipment.
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Intracerebral Microdialysis. Microdialysis allows for determina-
tion of the cerebral extracellular free drug concentration over a
period of time with calculation of the Kp,uu. This free drug
fraction represents the active form of the drug. Microdialysis
requires the implantation of a dialysis probe in a selected area of
the brain of the animal. This microdialysis probe consists of a
semipermeable membrane that is continuously infused with
physiological solution (217). Therefore, the compounds that
are able to permeate through the membrane will diffuse
according to the concentration gradient. This procedure does
not require a specific mode of administration, and the perme-
ation of the tested compound can be monitored after oral,
intravenous, subcutaneous or infusion administration.
Therefore, any drug entering the brain, which is always the
unbound fraction of the drug, will be monitored over time in
the extracellular fluid of the same animal (218) using HPLC,
UHPLC or capillary electrophoresis. This technique requires a
reduced number of animals for the pharmacokinetics determi-
nation compared to other techniques (71). Moreover, because
the same animal is monitored, there is no deviation due to
variation in the population, gender or age of the animal.
However, implantation of the dialysis system may locally dis-
rupt the BBB, leading to a possible misinterpretation of the
results. Moreover, highly lipophilic compounds can be
adsorbed onto the probe, leading to mass-balance errors. This
technique is more appropriate for moderately permeable
compounds.
Intracerebral microdialysis was used by Gupta et al.
(219) to compare the BBB transport and CNS distribution
of two cetirizine enantiomers, the R and the S forms, to
evaluate the stereoselectivity that occurs at the BBB. They
compared the Kp (total brain to total plasma concentra-
tions), Kp,u (total brain to unbound plasma concentrations)
and Kp,uu (unbound brain to plasma concentrations) for
both enantiomers. Whereas the Kp value could have led
to the interpretation that brain penetration was
stereoselective for both isomers (Kp=0.22 for S-cetirizine
and 0.04 for R-cetirizine), the Kp,u (0.44 for S-cetirizine
and 0.22 for R-cetirizine) indicates that plasma protein
binding greatly influences the biodistribution of both forms
of the antihistamine. The unbound fraction was found to
be 0.50 for S-cetirizine but only 0.15 for R-cetirizine.
When considering both the plasma protein binding and
brain tissue binding, they discovered that the Kp,uu values
were similar for both enantiomers (Kp,uu=0.17 for S-
cetirizine and 0.14 for R-cetirizine). These similar values
indicate that both enantiomers are effluxed at the BBB
(Kp,uu<1) and that no significant difference occurs in their
transport. The information generated by these in vivo
methodologies that are able to distinguish between the
active (unbound fraction) and inactive forms of the drugs
are therefore able to reliably determine the biodistribution
profile of a drug at the BBB.
The In Vitro Brain Slice Uptake Experiment Combined with the
In Vivo Kp. Determination of the entire concentration of a
drug in the brain in vivo, combined with the volume of distri-
bution of the unbound drug determined by an in vitro brain
slice uptake experiment, allows for calculation of the unbound
brain to plasma concentration ratio Kp,uu (220,221). In the
brain slice uptake experiment, the brain of a sacrificed animal
is removed and immersed in ice-cold oxygenated pH 7.4
buffer (221). Brain slices (300 μm) of striatal areas are cut with
a microslicer and preincubated with an extracellular fluid
buffer before addition of the drug. At specific incubation
times, the brain slices are removed from the solution of buffer
containing the drug, dried, weighed and homogenised for
determination of the amount of drug recovered in the brain
slice. The main advantage of this technique is in the determi-
nation of the pharmacologically active unbound fraction of
the drug in the brain. Moreover, the brain slices contain intact
cerebral endothelial cells with their functional transporters as
well as the same extra-to-intra-cellular pH gradient found
in vivo (220). By contrast, the throughput of this model is
limited due to the need for experimental animals and the
minimum incubation time needed to reach drug equilibrium
between the buffer and the brain slices, which is required to
calculate Vu, brain (220). As the incubation time to reach
equilibrium increases with the Vu, brain and the Vu, brain in-
creases with lipophilicity, the majority of compounds during
the drug discovery phases require longer and longer incuba-
tion timestime, which cannot be supported by the limited life
expectancy of the brain slices. Friden et al. evaluated this brain
slice uptake assay to rapidly determine the unbound drug
concentration in the brain (221). When they compared the
results that were obtained for 15 diverse compounds with
in vivo intracerebral microdialysis, they observed a reliable
correlation between both techniques.
The Brain Uptake Index (BUI) Technique
The brain uptake index model is appropriate for compounds
that moderately to rapidly penetrate the BBB and is gener-
ally performed in rats. A rapid bolus injection of 200 μl
buffered solution containing a known concentration of a
radiolabelled reference compound and the tested drug is
administered directly into the carotid artery of the rat. The
brain is then removed after 5–15 s and analysed for
radiolabelled contents (71) by scintillation counting. BUI
allows for determination of the log PS, which is the perme-
ability multiplied by the surface area. This technique is based
on the following three hypotheses: the time between injection
and decapitation is so short that no metabolism occurs before
the brain is removed; the compound can diffuse from the
blood to the brain; and when the compound is in the brain, it
cannot go back into the blood (222). The main drawback of
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this technique is that extremely low concentrations of drug
are present in the brain because of the very short analysis
time, which causes sensitivity problems for compounds with
low permeability. This technique is more appropriate for
compounds with a high permeability through the BBB. For
example, this technique has been used by Oldendorf et al.,
who demonstrated modulation of the transporter activity
under different pH conditions (223).
The In Situ Brain Perfusion
In situ brain perfusion is suitable for low to high permeant
compounds (43) or substrates of an endogenous transport
system. This model provides the same information as the
BUI but with higher sensitivity. In situ brain perfusion is
performed on an artificial cerebral circuit, resulting from
the ligature of some cerebral arteries and catheterisation of
the external carotid artery. Therefore, the flow rate and dura-
tion of perfusion are known and can be controlled. The brain is
then perfused with an oxygenated hydrogenocarbonate buffer
containing a known amount of radiolabeled compound.
Determination of the radioactivity at a predefined time,
ranging from 5 s to 30 min,) allows for the direct
determination of pharmacokinetics parameters, particularly
the volume of distribution and the rate of compound transfer,
Kin (43,224).
Because the composition of the perfusate is controlled, in
situ brain perfusion allows for the determination of PS values
without considering either metabolism or plasma and brain
protein binding. Only the intact form of the drug reaches the
brain. This method provides information regarding the time
required for the compound to cross the BBB. Moreover, the
amount of drug reaching the brain is fully controlled.
Compared to the BUI, the sensitivity of in situ brain perfusion
is much higher because of a longer exposition time of the
brain (126). This method is particularly interesting for deter-
mination of the kinetics of saturable transport at the BBB.
In situ brain perfusion was used by Cannon et al. (225) to
study the modulation of P-gp/ABCB1 activity. They found
that activation of the sphingosine-1-phosphate receptor by a
specific ligand such as sphingosine-1-phosphate led to a
decrease in P-gp/ABCB1 activity. The activity returned to
the basal state after the administration of sphingosine-1-
phosphate receptor antagonist. They concluded that this
strategy could be used to increase the CNS bioavailability
of P-gp substrates, such as verapamil or loperamide.
The Brain Efflux Index
The brain efflux index has been developed to determine the
presence of a potential efflux pathway at the BBB when the
compound is postulated to be transported from the brain to
the blood. This technique is generally used to understand
why a sufficiently lipophilic compound fails to penetrate the
brain (211).
Briefly, the test and reference compounds are microinjected
directly into the brain tissue. After a predefined time, the brain
is removed and the tissues are analysed to determine the
concentration of the residual compounds.
This protocol requires the use of a highly sensitive method
to determine the small amounts of compounds that may be
present. Moreover, the researcher must be careful during the
microinjection because a rapid or careless manipulation will
irreversibly damage the BBB and confound the resulting
measured permeability. The major drawback of this tech-
nique is the sacrifice of a large number of rats at different
time points.
Kakee et al. (226) used this technique to highlight the
saturable efflux transport of para-aminohippuric acid at the
BBB. A comparison of the apparent efflux clearance that was
obtained in this study using the brain efflux index method
with the apparent influx clearance obtained by BUI con-
firmed the selective transport of the carboxylic acid under
investigation from the brain to the blood.
Non-Invasive Imaging Techniques
Non-invasive imaging techniques have been developed to
qualitatively and quantitatively determine the permeation
of drugs in vivo. Moreover, imaging can also be used to
identify P-gp/ABCB1 inhibitors or P-gp/ABCB1 substrates
(227) or to determine the BCRP activity at the BBB (228).
These techniques are primarily positron emission tomogra-
phy (PET), magnetic resonance imaging or magnetic reso-
nance spectroscopy. Because these techniques are non-
invasive, they can be used in humans and allow for the
determination of personalised pharmacokinetics. Imaging is
also used to detect BBB damages in patients suffering from a
stroke, brain tumours or multiple sclerosis. However, these
techniques require expensive equipment and labelled radio-
tracers. Sensitivity issues may be encountered, particularly
with magnetic resonance imaging (126). Knight et al. used
magnetic resonance imaging to localise and quantify the
BBB opening in a rat model under ischaemic conditions
af ter the intravenous infus ion of gadol in ium-
diethylenetriamine pentaacetic acid to achieve a blood con-
centration (229). Under normal conditions, this substance
should not penetrate the brain. Other researchers, such as
Serres et al., established a promising approach for the early
diagnosis of brain tumors by targeting brain metastasis with
iron oxide microparticles loaded with contrast agents (230).
Magnetic resonance imaging allowed for the visualisation of
brain metastases with 3-fold greater sensitivity than conven-
tional tumour diagnostics.13C magnetic resonance spectros-
copy was used to assess the relationship between brain and
plasma concentrations of glucose in patients suffering from
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diabetes type I during a hypoglycaemichypoglycemia event
(231).
Therefore, imaging is an efficient approach to determine
personalised permeabilities during or after a pathological
event. The main advantage of this technique is that it can
be conducted in human for specific purposes and with safe
drugs or dyes. Moreover, the distribution profile can be
visualised, identifying the targeted regions of the brain.
CONCLUSIONS
The specific organisation of the cerebral endothelial cells
forming the BBB causes multiple problems for a drug that
needs to reach the central nervous system. Additionally, the
BBB is not only a physical barrier but also a pharmacological
and a metabolic barrier due to the expression of numerous
transporters and the presence of a variety of enzymes. These
features are the reason why attrition rate is so high for CNS
drug candidates. However, the population worldwide is aging
and by 2050, elderly people over the age of 65 will represent
16% of the population (43). Along with this global aging, CNS
disorders, such as Alzheimer’s disease, increase exponentially,
whereas treatments are lacking. Thus, there is a real need to
either improve CNS drug discovery or to change the CNS
drug delivery strategy by using colloidal vectorisation. The
second option has garnered great interest during the last few
decades. Vectorisation of active CNS drugs and mRNA or
peptides with carriers that are able to recognise a specific
target at the BBB are no longer impossibilities.
Themain questions that remain to be answered in the early
drug discovery and development processes are as follows: is
the chemical CNS active? Is the drug a substrate of influx or
efflux transporters? Is the drug bioavailable? Is it easily
metabolised? As described in this review, many tools are
available to predict and/or understand the mode of transport
of a new chemical entity (NCE) through the BBB. These tools
include computational sciences, in vitro and in vivo models and
knowledge regarding new transporters. However, it is clear
that a combination of methods, even in vitro models, should
provide more relevant information regarding the potential of
a drug to penetrate the BBB. Each method provides specific
insight into the transport condition of NCEs, and only proper
knowledge of the specificities of each model will help scientists
to decrease the compound attrition rate. In vivo models pro-
vide much more global information regarding the BBB per-
meation of NCEs than other models. However, even simple
models, such as artificial membranes, should not be neglected
in the discovery process. Although these models provide nei-
ther a global view nor a realistic tool for the selection of
compounds, they are useful for understanding the transport
mechanism. The simplicity of these models isolates de facto
unique or a limited number of aspects of the entire transport
process. Similarly, although some cellular models do not
provide sufficient relevancy in terms of BBB prediction, par-
ticularly regarding the tightness of the intercellular junctions
as evaluated by TEER measurement and/or the permeation
of sucrose, they constitute an extraordinarily predictive and
sometimes selective tool for medicinal chemists if the data are
well interpreted.
All of these models that are used for the evaluation of BBB
penetration by NCEs may also provide information regard-
ing the penetration of colloidal vectors and other
nanocarriers. Currently during the drug discovery and de-
velopment processes, an increasing number of delivery sys-
tems must be tested for efficacy; but, few models have been
used and validated for the screening of new formulations.
Moreover, kinetic parameters of carrier degradation that
influence drug release should also be taken into consider-
ation when evaluating a new model. Therefore, existing
methods to predict or characterise BBB permeability need
to adapt to these new drug delivery systems in order to fully
understand their mode of action.
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